Inactive Instrument

Cardiome Pharma Corp. Share Price Nasdaq

Equities

CA14159U2020

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for Cardiome Pharma Corp.
Sales 2018 28.67M 2.39B Sales 2019 32.63M 2.72B Capitalization 27.28M 2.27B
Net income 2018 -16M -1.33B Net income 2019 -35M -2.92B EV / Sales 2018 5.13 x
Net Debt 2018 25.92M 2.16B Net Debt 2019 33.9M 2.83B EV / Sales 2019 1.87 x
P/E ratio 2018
-7.1 x
P/E ratio 2019
-0.68 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 86.23%
More Fundamentals * Assessed data
Members of the board TitleAgeSince
Director/Board Member - -
Director/Board Member 53 -
Director/Board Member - -
More insiders
Correvio Pharma Corp is a Canada-based company, which is a specialty pharmaceutical company. The Company focused on providing acute services. It's portfolio brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Its products include Trevyent, a drug-device combination that is designed to deliver treprostinil, the treatment for pulmonary arterial hypertension.
More about the company